Anaphylaxis in patients with congenital bleeding disorders and inhibitors

Blood Coagulation and Fibrinolysis

Volumn 20, Issue 4, 2009, Pages 225-229

  Franchini, Massimo ^a   Lippi, Giuseppe ^b   Montagnana, Martina ^b   Targher, Giovanni ^c   Zaffanello, Marco ^c   Salvagno, Gian Luca ^c   Rivolta, Gianna Franca ^a   Perna, Caterina Di ^a   Tagliaferri, Annarita ^a  

^a UNIVERSITY HOSPITAL OF PARMA   (Italy)

^b Section of Clinical Chemistry   (Italy)

^c UNIVERSITY OF VERONA   (Italy)

Author keywords

Anaphylaxis; Hemophilia; Inhibitors; Von willebrand disease

Indexed keywords

ALLOANTIBODY; ANTIHISTAMINIC AGENT; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR 9 CONCENTRATE; CYCLOPHOSPHAMIDE; HYDROCORTISONE; IMMUNOGLOBULIN; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 8; RISTOCETIN; RITUXIMAB; STEROID; VON WILLEBRAND FACTOR;

ANAPHYLAXIS; ANTIBODY BLOOD LEVEL; BLEEDING; BLEEDING DISORDER; CONTINUOUS INFUSION; CRYOPRECIPITATE; DESENSITIZATION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; GENE DELETION; HEMOPHILIA A; HEMOPHILIA B; HUMAN; MEMBRANOUS GLOMERULONEPHRITIS; NEPHROTIC SYNDROME; PATHOPHYSIOLOGY; PLASMAPHERESIS; PRIORITY JOURNAL; REVIEW; URTICARIA; VON WILLEBRAND DISEASE;

ANAPHYLAXIS; BLOOD COAGULATION DISORDERS, INHERITED; BLOOD COAGULATION FACTOR INHIBITORS; HUMANS; ISOANTIBODIES;

EID: 67649552847     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e328329f265     Document Type: Review

References (44)

1. Lusher JM. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group. N Engl J Me. 1993; 328:453-459.
2. Ehrenforth S, Kreuz W, Scharrer I, Linde R, Funk M, Güngör T, et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lance. 1992; 339:594-598.
3. Jacquemin MG, Saint-Remy JM. Factor VIII alloantibodies in hemophilia. Curr Opin Hemato. 2004; 11:146-150.
4. Ofosu FA, Freedman J, Semple JW. Plasma-derived biological medicines used to promote haemostasis. Thromb Haemos. 2008; 99:851 -862.
5. Jadhav M, Warrier I. Anaphylaxis in patients with hemophilia. Semin Thromb Hemos. 2000; 26:205-208.
6. Clapp R, Green D. Reaction to rapidly infused AHF cryoprecipitate. N Engl J Me. 1969; 281:329.
7. Helmer RE, Alperin JB, Yunginger JW, Grant JA. Anaphylactic reactions following infusion of factor VIII in a patient with classic hemophilia. Am J Me. 1980; 69:953-957.
8. Bove JR. Anaphylactic reaction to purified antihemophilic factor concentrate. Transfusio. 1988; 26:603.
9. Harper JL, Gill JC, Hopp RJ, Evans J, Haire WD. Induction of immune tolerance in a 7-year-old hemophiliac with an anaphylactoid inhibitor. Thromb Haemos. 1995; 74:1039-1041.
10. Shopnick Rl, Kazemi M, Brettler DB, Buckwalter C, Yang L, Bray G, et al. Anaphylaxis after treatment with recombinant factor VIII. Transfusio. 1996; 36:358-361.
11. Kadar JG, Schuster J, Hunzelmann N. IgE-mediated anaphylactic reaction to purified and recombinant factor VIII in a patient with severe haemophilia A. Haemophili. 2007; 13:104-105.
12. Tsuchiya H, Shima M, Yoshioka A. Anaphylactic response to factor VIII preparations in a haemophilic child with an inhibitor of high litre during the tolerance induction. Eur J Pediat. 1998; 157:85.
13. Pernod G, Armari C, Barro C, Plantaz D, Caperan D, Jacquot C, et al. Anaphylaxis following the use of a plasma-derived immunopurified monoclate-P, and the recombinant Recombinate and Kogenate factor VIII: a therapeutic challenge. Haemophili. 1999; 5:143-144.
14. Davis HM, Brown SK, Nash DW, Pennetti AM, Salzman PM, Schreiber AB, et al. Lack of immune response to mouse IgG in hemophilia A patients treated chronically with monoclate, a monoclonal antibody affinity purified factor VIII preparation. Thromb Haemos. 1990; 63:386-391.
15. Shakib F, Stanworth DR. lgG4: a possible mediator of anaphylaxis in a haemophiliac patient. Clin Allerg. 1979; 9:597-603.
16. Nilsson IM, Berntorp E, Zettervall O, Dahlbäck B. Noncoagulation inhibitory factor VIII antibodies after induction of tolerance to factor VIII in hemophilia A patients. Bloo. 1990; 75:378-383.
17. Jamieson DM, Stafford CT, Maloney MJ, Lutcher CL. Desensitization to factor VIII in a patient with classic hemophilia and C2 deficiency. Ann Allerg. 1987; 58:215-220.
18. Warrier I. Management of haemophilia B patients with inhibitors and anaphylaxis. Haemophili. 1998; 4:574-576.
19. Warrier I, Lusher JM. Development of anaphylactic shock in haemophilia B patients with inhibitors. Blood Coagul Fibrinolysi. 1998; 9 (Suppl 1): S125-S128.
20. Warrier I. Factor IX inhibitors and anaphylaxis in hemophilia B. J Pediatr Hematol Onco. 1997; 19:23-27.
21. Thorland EC, Drost JB, Lusher JM, Warrier I, Shapiro A, Koerper MA, et al. Anaphylactic response to factor IX replacement therapy in haemophilia B patients: complete gene deletions confer the highest risk. Haemophili. 1999; 5:101-105.
22. Tengborn L, Hansson S, Fasth A, Lubeck PO, Berg A, Ljung R. Anaphylactoid reactions and nephrotic syndrome: a considerable risk during factor IX treatment in patients with haemophilia B and inhibitors: a report on the outcome in two brothers. Haemophili. 1998; 4:854-859.
23. Barnes C, Rudzki Z, Ekert H. Induction of immune tolerance and suppression of anaphylaxis in a child with haemophilia B by simple plasmapheresis and antigen exposure. Haemophili. 2000; 6:693-695.
24. Barnes C, Brewin T, Ekert H. Induction of immune tolerance and suppression of anaphylaxis in a child with haemophilia B by simple plasmapheresis and antigen exposure: progress report. Haemophili. 2001; 7:439-440.
25. Alexander S, Hopewell S, Hunter S, Chouksey A. Rituximab and desensitization for a patient with severe factor IX deficiency, inhibitors, and history of anaphylaxis. J Pediatr Hematol Onco. 2008; 30:93-95.
26. Shibata M, Shima M, Misu H, Okimoto Y, Giddings JC, Yoshioka A. Management of haemophilia B inhibitor patients with anaphylactic reactions to FIX concentrates. Haemophili. 2003; 9:269-273.
27. Curry NS, Misbah SA, Giangrande PL, Keeling DM. Achievement of immune tolerance in a patient with haemophilia B and inhibitory antibodies, complicated by an anaphylactoid reaction. Haemophili. 2007; 13:328- 330.
28. Chuansumrit A, Moonsup Y, Sirachainan N, Benjaponpitak S, Suebsangad A, Wongwerawattanakoon P. The use of rituximab as an adjuvant for immune tolerance therapy in a hemophilia B boy with inhibitor and anaphylaxis to factor IX concentrate. Blood Coagul Fibrinolysi. 2008; 19:208-211.
29. Sawamoto Y, Shima M, Yamamoto M, Kamisue S, Nakai H, Tanaka I, et al. Measurement of antifactor IX IgG subclasses in haemophilia B patients who developed inhibitors with episodes of allergic reactions to factor IX concentrates. Thromb Re. 1996; 83:279-286.
30. Dioun AF, Ewenstein BM, Geha RS, Schneider LC. IgE-mediated allergy and desensitization to factor IX in hemophilia B. J Allergy Clin Immuno. 1998; 102:113-117.
31. Nillson IM, Berntorp E, Zettervall O. Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide, and factor VIII. W Engl J Me. 1988; 318:947-950.
32. Ewenstein BM, Takemoto C, Warrier I, Lusher J, Saidi P, Eisele J, et al. Nephrotic syndrome as a complication of immune tolerance in hemophilia B. Stoo. 1997; 89:1115-1116.
33. Warrier I. Factor IX inhibitors and anaphylaxis. In Rodriguez-Merchan EC, Lee CA, editors. Inhibitors in patients with haemophilia. Blackwell Publishing; 2002. pp. 87-91.
34. Mannucci PM, Meyer D, Ruggeri ZM, Koutts J, Ciavarella N, Lavergne JM. Precipitating antibodies in von Willebrand's disease. Natur. 1976; 262:141-142.
35. Shelton-lnloes BB, Chehab FF, Mannucci PM, Federici AB, Sadler JE. Gene deletions correlate with the development of alloantibodies in von Willebrand disease. J Clin Inves. 1987; 79:1459-1465.
36. Tout H, Obert B, Houllier A, Fressinaud E, Rothschild C, Meyer D, ef a/. Mapping and functional studies of two alloantibodies developed in patients with type 3 von Willebrand disease. Thromb Haemos. 2000; 83:274-281.
37. Mannucci PM, Ruggeri ZM, Ciavarella N, Kazatchkine MD, Mowbray JF. Precipitating antibodies to factor Vlll/von Willebrand factor in von Willebrand's disease: effects on replacement therapy. Stoo. 1981; 57:25-31.
38. Bergamaschini L, Mannucci PM, Federici AB, Coppola R, Guzzoni S, Agostoni A. Posttransfusion anaphylactic reactions in a patient with severe von Willebrand disease: role of complement and alloantibodies to von Willebrand factor. J Lab Clin Me. 1995; 125:348-355.
39. Batlle J, Loures E, Vila P, Hernandez MC, Mendez JA, Torea J, et al. Alloantibody from a patient with severe von Willebrand disease inhibits von Willebrand factor-factor VIII interaction. Ann Hemato. 1997; 75:111 - 115.
40. Mannucci PM, Tamaro G, Narchi G, Candotti G, Federici A, Altieri D, et al. Life-threatening reaction to factor VIII concentrate in a patient with severe von Willebrand disease and alloantibodies to von Willebrand factor. Eur J Haemato. 1987; 39:467-470.
41. Franchini M, Gandini G, Giuffrida A, De Gironcoli M, Federici AB. Treatment for patients with type 3 von Willebrand disease and alloantibodies: a case report. Haemophili. 2008; 14:645-646.
42. Boyer-Neumann C, Dreyfus M, Wolf M, Veyradier A, Meyer D. Multitherapeutic approach to manage delivery in an alloimmunized patient with type 3 von Willebrand disease. J Thromb Haemos. 2003; 1:190-191.
43. Ciavarella N, Schiavoni M, Valenzano E, Mangini F, Inchingolo F. Use of recombinant factor Vila (NovoSeven) in the treatment of two patients with type III von Willebrand's disease and an inhibitor against von Willebrand factor. Haemostasi. 1996; 26 (Suppl 1):150-154.
44. Grossmann RE, Geisen U, Schwender S, Keller F. Continuous infusion of recombinant factor Vila (NovoSeven) in the treatment of a patient with type III von Willebrand's disease and alloantibodies against von Willebrand factor. Thromb Haemos. 2000; 83:633-634.